The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy

Yadong Guo, Donghui Shi, Junfeng Zhang, Shiyu Mao, Longsheng Wang, Wentao Zhang, Ziwei Zhang, Liang Jin, Bin Yang, Lin Ye, Xudong Yao, Yadong Guo, Donghui Shi, Junfeng Zhang, Shiyu Mao, Longsheng Wang, Wentao Zhang, Ziwei Zhang, Liang Jin, Bin Yang, Lin Ye, Xudong Yao

Abstract

Objective: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been shown to be an important prognostic marker in some tumor types. The aim of this study was to evaluate the prognostic impact of the preoperative HALP score, with the intent to develop a new prognostic index for patients with metastatic prostate cancer (mPCA) after cytoreductive radical prostatectomy (cRP). Methods: We retrospectively analyzed the data from 82 patients with mPCA after cRP in our institution. Of these patients, 70 patients were diagnosed with oligometastatic prostate cancer (oPCA). The main outcome measure was prostate-specific antigen (PSA) progression-free survival (PFS), which was assessed using Kaplan-Meier curves with log-rank statistics. In addition, univariate and multivariate Cox regression analyses were performed to determine the prognostic factors associated with PSA-PFS. The prediction accuracy was evaluated by assessing the area under the receiver operating characteristic (AUC) curve. Results: The median follow-up time for all patients was 17.47 months (range: 11.73-24.38 months). Based on the Kaplan-Meier curve analysis, it was noticed that a low preoperative HALP value (<32.4) was significantly associated with a decreased PSA-PFS in both the mPCA and oPCA subgroups (P < 0.001, P = 0.002, respectively). In addition, multivariate analysis predicted that a low HALP score was a common independent prognostic factor of an overall shorter PSA-PFS (HR: 0.352; range: 0.154-0.804; P = 0.013). However, among the different subgroups, a low HALP score (HR: 0.275; range: 0.116-0.653; P = 0.003) was confirmed to be an independent predictor of a shorter PSA-PFS in patients from the oPCA subgroup. Furthermore, the effective combination of the pathologic Gleason score (PGS) and the HALP score (HALPG) as a new index was found to be an independent risk factor. Also, the AUC of the HALPG score for PSA-PFS was observed to be higher than other conventional clinical indices. Conclusion: Overall, our results confirmed the HALP score as an independent prognostic factor for PSA-PFS in patients with mPCA or oPCA after cRP. Moreover, the new index, HALPG, also appeared to be an independent prognostic factor and was better than the HALP score. Importantly, it is evident that this new prognostic index has the ability to accurately identify patients at low, intermediate, and high risk of recurrence, thus easily allowing informed treatment decisions to be made.

Keywords: albumin; and platelet (HALP) score; hemoglobin; lymphocyte; metastatic prostate cancer; prognostic model.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Cutoff values for HALP, PLR and NLR, as determined by X-tile software.
Figure 2
Figure 2
Kaplan-Meier curves for PSA-PFS in mPCA (A, B, C) and oPCA (D, E, F) patients according to the HALP score, PLR, and NLR, respectively.
Figure 3
Figure 3
Kaplan-Meier curves of mPCA (A) and oPCA (B) patients based on the HALPG score.
Figure 4
Figure 4
Comparison of the predictive ability of the HALPG score and other clinical parameters by ROC curve analysis in mPCA and oPCA patients.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
    1. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352–60.
    1. Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R. et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73:178–211.
    1. Mathieu R, Korn SM, Bensalah K, Kramer G, Shariat SF. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? World J Urol. 2017;35:567–77.
    1. Hellman S, Weichselbaum R. Oligometastases. J Clin Oncol. 1995;13:8–10.
    1. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP. et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? International Journal of Radiation Oncology*Biology*Physics. 2004;58:3–10.
    1. James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.
    1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.
    1. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.
    1. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010;22:215–22.
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
    1. Coussens L, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
    1. Coffelt S, de Visser K. Cancer: Inflammation lights the way to metastasis. Nature. 2014;507:48–9.
    1. Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H. et al. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate. 2018;78:250–6.
    1. Sidaway P. Prostate cancer: Platelet-to-lymphocyte ratio predicts prostate cancer prognosis. Nat Rev Urol. 2015;12:238.
    1. Lorente D, Mateo J, Templeton A, Zafeiriou Z, Bianchini D, Ferraldeschi R. et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26:750–5.
    1. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL. et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243–74.
    1. Fan L, Wang X, Chi C, Wang Y, Cai W, Shao X. et al. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. Prostate. 2017;77:1233–41.
    1. Liu X, Meng QH, Ye Y, Hildebrandt MA, Gu J, Wu X. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015;36:243–8.
    1. Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214–21.
    1. Peng D, Zhang C, Tang Q, Zhang L, Yang K, Yu X. et al. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy. BMC Urol. 2018;18:20.
    1. Peng D, Zhang C, Gong Y, Hao H, Guan B, Li X. et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 2018;8:794.
    1. Chen X, Xue L, Wang W, Chen H, Zhang W, Liu K. et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6:41370–82.
    1. Jiang H, Li H, Li A, Tang E, Xu D, Chen Y. et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 2016;7:72076–83.
    1. Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.
    1. Ryan A, Power D, Daly L, Cushen S, Ní Bhuachalla Ē, Prado C. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75:199–211.
    1. Efremova M, Rieder D, Klepsch V, Charoentong P, Finotello F, Hackl H. et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun. 2018;9:32.
    1. Belcher D, Ju J, Baek J, Yalamanoglu A, Buehler P, Gilkes D. et al. The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: A theoretical and experimental study. PLoS ONE. 2018;13:e0191275.
    1. Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296:989–95.
    1. Sejima T, Iwamoto H, Masago T, Morizane S, Yao A, Isoyama T. et al. Low pre-operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients. Cent European J Urol. 2013;66:126–32.
    1. Shiao S, Chu G, Chung L. Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett. 2016;380:340–8.
    1. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143:819–26.
    1. Schumacher D, Strilic B, Sivaraj K, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24:130–7.
    1. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.
    1. Andrén O, Fall K, Franzén L, Andersson S, Johansson J, Rubin M. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006;175:1337–40.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться